Skip to main content
. 2020 Feb 11;1(1):100001. doi: 10.1016/j.jtocrr.2020.100001

Figure 2.

Figure 2

Biologics that modulate the IL-1 pathway.54,82 The IL-1α and IL-1β signaling pathways can be inhibited by several biologics. Anakinra, a selective IL-1R1 antagonist, and rilonacept, a soluble decoy receptor, can inhibit the activity of both IL-1α and IL-1β. AMG 108 can bind to IL-1R1 to inhibit the activity of IL-1α and IL-1β. Protein chimera EBI-005 inhibits IL-1 signaling by binding to IL-1R1. Bermekimab is a monoclonal antibody that targets IL-1α. Canakinumab is an anti–IL-1β human monoclonal IgG1 antibody. Gevokizumab and LY2189102 are IL-1β neutralizing antibodies. IL-1β, interleukin 1 beta; IL-1α, interleukin 1 alpha; IL-1R, IL-1 receptor; IgG1, immunoglobulin G1.